Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target

Core Insights - Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is highlighted as a promising investment opportunity with a 'Buy' rating and a price target of $100, indicating a potential upside of nearly 172% from the current price [1] - The company's lead candidate, Claseprubart, is recognized as a "best-in-class complement inhibitor" and is positioned to improve treatment standards for three autoimmune conditions: generalized myasthenia gravis (gMG), chronic idiopathic demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN), each representing a market of up to $2 billion [1] - Dianthus Therapeutics has achieved a year-to-date return of 68.39%, outperforming the market average by 55.43% [2] Company Overview - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, founded in 2019, focusing on solutions for patients with severe autoimmune and inflammatory diseases [3] - The company aims to enhance the selectivity of complement therapeutics, which is crucial for treating autoimmune conditions [3]